Cargando…

Evaluation of the Tobbstop Mobile App for Smoking Cessation: Cluster Randomized Controlled Clinical Trial

BACKGROUND: Mobile apps provide an accessible way to test new health-related methodologies. Tobacco is still the primary preventable cause of death in industrialized countries, constituting an important public health issue. New technologies provide novel opportunities that are effective in the cessa...

Descripción completa

Detalles Bibliográficos
Autores principales: Pallejà-Millán, Meritxell, Rey-Reñones, Cristina, Barrera Uriarte, Maria Luisa, Granado-Font, Esther, Basora, Josep, Flores-Mateo, Gemma, Duch, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381259/
https://www.ncbi.nlm.nih.gov/pubmed/32589153
http://dx.doi.org/10.2196/15951
_version_ 1783563011396468736
author Pallejà-Millán, Meritxell
Rey-Reñones, Cristina
Barrera Uriarte, Maria Luisa
Granado-Font, Esther
Basora, Josep
Flores-Mateo, Gemma
Duch, Jordi
author_facet Pallejà-Millán, Meritxell
Rey-Reñones, Cristina
Barrera Uriarte, Maria Luisa
Granado-Font, Esther
Basora, Josep
Flores-Mateo, Gemma
Duch, Jordi
author_sort Pallejà-Millán, Meritxell
collection PubMed
description BACKGROUND: Mobile apps provide an accessible way to test new health-related methodologies. Tobacco is still the primary preventable cause of death in industrialized countries, constituting an important public health issue. New technologies provide novel opportunities that are effective in the cessation of smoking tobacco. OBJECTIVE: This paper aims to evaluate the efficacy and usage of a mobile app for assisting adult smokers to quit smoking. METHODS: We conducted a cluster randomized clinical trial. We included smokers older than 18 years who were motivated to stop smoking and used a mobile phone compatible with our mobile app. We carried out follow-up visits at 15, 30, and 45 days, and at 2, 3, 6, and 12 months. Participants of the intervention group had access to the Tobbstop mobile app designed by the research team. The primary outcomes were continuous smoking abstinence at 3 and 12 months. RESULTS: A total of 773 participants were included in the trial, of which 602 (77.9%) began the study on their D-Day. Of participants in the intervention group, 34.15% (97/284) did not use the app. The continuous abstention level was significantly larger in the intervention group participants who used the app than in those who did not use the app at both 3 months (72/187, 38.5% vs 13/97, 13.4%; P<.001) and 12 months (39/187, 20.9% vs 8/97, 8.25%; P=.01). Participants in the intervention group who used the app regularly and correctly had a higher probability of not being smokers at 12 months (OR 7.20, 95% CI 2.14-24.20; P=.001) than the participants of the CG. CONCLUSIONS: Regular use of an app for smoking cessation is effective in comparison with standard clinical practice. TRIAL REGISTRATION: Clinicaltrials.gov NCT01734421; https://clinicaltrials.gov/ct2/show/NCT01734421
format Online
Article
Text
id pubmed-7381259
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-73812592020-08-07 Evaluation of the Tobbstop Mobile App for Smoking Cessation: Cluster Randomized Controlled Clinical Trial Pallejà-Millán, Meritxell Rey-Reñones, Cristina Barrera Uriarte, Maria Luisa Granado-Font, Esther Basora, Josep Flores-Mateo, Gemma Duch, Jordi JMIR Mhealth Uhealth Original Paper BACKGROUND: Mobile apps provide an accessible way to test new health-related methodologies. Tobacco is still the primary preventable cause of death in industrialized countries, constituting an important public health issue. New technologies provide novel opportunities that are effective in the cessation of smoking tobacco. OBJECTIVE: This paper aims to evaluate the efficacy and usage of a mobile app for assisting adult smokers to quit smoking. METHODS: We conducted a cluster randomized clinical trial. We included smokers older than 18 years who were motivated to stop smoking and used a mobile phone compatible with our mobile app. We carried out follow-up visits at 15, 30, and 45 days, and at 2, 3, 6, and 12 months. Participants of the intervention group had access to the Tobbstop mobile app designed by the research team. The primary outcomes were continuous smoking abstinence at 3 and 12 months. RESULTS: A total of 773 participants were included in the trial, of which 602 (77.9%) began the study on their D-Day. Of participants in the intervention group, 34.15% (97/284) did not use the app. The continuous abstention level was significantly larger in the intervention group participants who used the app than in those who did not use the app at both 3 months (72/187, 38.5% vs 13/97, 13.4%; P<.001) and 12 months (39/187, 20.9% vs 8/97, 8.25%; P=.01). Participants in the intervention group who used the app regularly and correctly had a higher probability of not being smokers at 12 months (OR 7.20, 95% CI 2.14-24.20; P=.001) than the participants of the CG. CONCLUSIONS: Regular use of an app for smoking cessation is effective in comparison with standard clinical practice. TRIAL REGISTRATION: Clinicaltrials.gov NCT01734421; https://clinicaltrials.gov/ct2/show/NCT01734421 JMIR Publications 2020-06-26 /pmc/articles/PMC7381259/ /pubmed/32589153 http://dx.doi.org/10.2196/15951 Text en ©Meritxell Pallejà-Millán, Cristina Rey-Reñones, Maria Luisa Barrera Uriarte, Esther Granado-Font, Josep Basora, Gemma Flores-Mateo, Jordi Duch. Originally published in JMIR mHealth and uHealth (http://mhealth.jmir.org), 26.06.2020. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR mHealth and uHealth, is properly cited. The complete bibliographic information, a link to the original publication on http://mhealth.jmir.org/, as well as this copyright and license information must be included.
spellingShingle Original Paper
Pallejà-Millán, Meritxell
Rey-Reñones, Cristina
Barrera Uriarte, Maria Luisa
Granado-Font, Esther
Basora, Josep
Flores-Mateo, Gemma
Duch, Jordi
Evaluation of the Tobbstop Mobile App for Smoking Cessation: Cluster Randomized Controlled Clinical Trial
title Evaluation of the Tobbstop Mobile App for Smoking Cessation: Cluster Randomized Controlled Clinical Trial
title_full Evaluation of the Tobbstop Mobile App for Smoking Cessation: Cluster Randomized Controlled Clinical Trial
title_fullStr Evaluation of the Tobbstop Mobile App for Smoking Cessation: Cluster Randomized Controlled Clinical Trial
title_full_unstemmed Evaluation of the Tobbstop Mobile App for Smoking Cessation: Cluster Randomized Controlled Clinical Trial
title_short Evaluation of the Tobbstop Mobile App for Smoking Cessation: Cluster Randomized Controlled Clinical Trial
title_sort evaluation of the tobbstop mobile app for smoking cessation: cluster randomized controlled clinical trial
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381259/
https://www.ncbi.nlm.nih.gov/pubmed/32589153
http://dx.doi.org/10.2196/15951
work_keys_str_mv AT pallejamillanmeritxell evaluationofthetobbstopmobileappforsmokingcessationclusterrandomizedcontrolledclinicaltrial
AT reyrenonescristina evaluationofthetobbstopmobileappforsmokingcessationclusterrandomizedcontrolledclinicaltrial
AT barrerauriartemarialuisa evaluationofthetobbstopmobileappforsmokingcessationclusterrandomizedcontrolledclinicaltrial
AT granadofontesther evaluationofthetobbstopmobileappforsmokingcessationclusterrandomizedcontrolledclinicaltrial
AT basorajosep evaluationofthetobbstopmobileappforsmokingcessationclusterrandomizedcontrolledclinicaltrial
AT floresmateogemma evaluationofthetobbstopmobileappforsmokingcessationclusterrandomizedcontrolledclinicaltrial
AT duchjordi evaluationofthetobbstopmobileappforsmokingcessationclusterrandomizedcontrolledclinicaltrial